Remestan

Quick links to important sections

Remestan

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Remestan

Quick Facts

Property Description
Active ingredient Temazepam
Form Oral solid preparation (Capsules or Tablets)
Pharmacological class Benzodiazepine (Hypnotic agent)
Common use Addressing sleep disorders / Promoting sleep onset
Origin Synthetic compound

What Type of Medicine is Remestan?

Remestan is a prescription-only medicine whose active ingredient is Temazepam, a synthetic compound derived from 3-hydroxy diazepam, clinically recognized for its reliable sedative properties. This drug is formally classified within the benzodiazepine pharmacological class and is specifically categorized as an intermediate-acting agent, distinguishing its duration from ultra-short or long-acting analogues. Remestan is generally positioned for adult patients struggling with acute or chronic sleep disorders and functions as a psychotropic agent by inducing general Central Nervous System (CNS) depression.

Composition and Therapeutic Purpose

The fundamental composition of Remestan consists of the active ingredient Temazepam delivered as a single-ingredient product (monotherapy). The drug is commonly supplied as oral solid capsules or tablets, utilizing standard pharmaceutical excipients necessary for formulating this drug form. The medication’s core therapeutic purpose is to alleviate persistent difficulty with sleep onset and maintenance. This is achieved by enhancing the effect of the neurotransmitter Gamma-Aminobutyric acid (GABA), which slows down excessive neuronal communication and facilitates the state of relaxation required for the onset of sleep.

Regulatory References

  1. NIH StatPearls review

What side effects are possible with Remestan?

Possible Side Effects and Safety Information

The safety profile of Remestan (Temazepam), a benzodiazepine hypnotic agent, is characterized primarily by adverse effects related to Central Nervous System (CNS) depression, as documented in official regulatory labeling.

Documented Adverse Reactions and Safety Patterns

In regulatory-reviewed clinical data, the most common adverse reactions are generally effects that may persist the following day, including drowsiness, headache, fatigue, lethargy, and dizziness. Other common effects include nausea, nervousness, anxiety, confusion, and a hangover effect. These effects are typically classified under Nervous System and Psychiatric Disorders in regulatory system-organ classifications.

The official labeling notes the potential for complex sleep behaviors like sleep-driving or performing activities while not fully awake and having no memory of the event (anterograde amnesia) afterward. The risk of physical dependence and a severe withdrawal syndrome—potentially including anxiety, tremors, or seizures—is also explicitly noted, particularly after extended use or rapid discontinuation.

Serious Safety Concerns and Contraindications

Regulatory documents highlight the risk of serious adverse reactions, including respiratory depression, profound sedation, and coma, particularly when the medicine is used concurrently with other CNS depressants such as opioids. Rare but severe hypersensitivity reactions like anaphylaxis and angioedema are also documented safety events.

Specific contraindications apply to certain patient populations. Remestan is contraindicated in patients with severe hepatic insufficiency and those with severe respiratory impairment due to heightened risks. Furthermore, use during pregnancy is generally contraindicated based on the potential for fetal harm and neonatal CNS depression.

Overdose and Emergency Response

Overdose Manifestations and Severity

Overdosage of Remestan is characterized by an escalating spectrum of Central Nervous System (CNS) depression. Documented clinical manifestations begin with somnolence, drowsiness, and confusion, potentially progressing to loss of consciousness, coma, and reduced reflexes.

Severe Outcomes and Required Emergency Action

Official regulatory documents list profound respiratory depression, hypotension, and death as severe, life-threatening outcomes, especially when the drug is co-ingested with other CNS depressants, such as alcohol or opioids.

Immediate medical attention must be sought if an overdose is suspected. Urgent medical help is explicitly required if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Official Overdose Management

Treatment for overdose is primarily symptomatic and supportive, requiring close observation for signs of respiratory compromise.

  • Antidote Status: Flumazenil, a specific benzodiazepine antagonist, is available as a reversal agent. Its use, however, is subject to regulatory constraint due to the documented risk of inducing seizures in certain overdose settings.
  • Population Notes: Elderly patients are documented as being more susceptible to CNS effects such as confusion and unsteadiness, which can increase the risk of adverse outcomes.

Therapeutic Uses of Remestan

What Remestan Treats: Main Uses and Benefits

Remestan is commonly used for the short-term management of insomnia that has become severe or debilitating, where sleep symptoms are creating noticeable physiological strain. Its use is relevant for managing sleep problems that are acute or transient, contributing to easing the overall symptom load during these episodes.

The medication is considered relevant for managing symptoms that interfere with daily comfort, such as difficulty initiating sleep and struggles with sleep maintenance, including frequent nocturnal awakenings and early morning waking. This therapeutic profile is relevant in conditions presenting with acute episodes and those involving recurrent or episodic manifestations.

Remestan is often used when short-term symptomatic assistance is needed during phases where sleep disruption is triggered by acute situational factors or stress, or during adjustments like shift work. It provides supportive relief for adult and geriatric patients when symptoms that interfere with daily functioning become temporarily overwhelming.


Quick Fact: Relief for Sleep Disruption

Domain Focus
Symptom Profile Difficulty initiating sleep, nocturnal awakenings, early morning waking
Use Context Short-term symptomatic support for severe/debilitating insomnia
Patient Benefit Supports sleep continuity and helps reduce the symptom load

Regulatory References

  1. NIH StatPearls review

Eligibility and Restrictions for Use

Who can and cannot use Remestan?

Eligibility for Remestan is strictly defined by regulatory bodies and official prescribing information, primarily based on age, physiological state, and co-existing medical conditions.

Official Eligibility Constraints

Classification Population/Condition Regulatory Status (Official Wording)
Contraindicated Women who are or may become pregnant Prohibited (Risk of fetal harm)
Severe hepatic insufficiency or acute pulmonary insufficiency Prohibited (Risk of severe adverse event)
Sleep apnoea syndrome or severe respiratory depression Prohibited
Use Not Established Children and adolescents (under 18 years) Not Recommended (Safety and efficacy not established)
Conditional Use Older adults (geriatric patients) Use is permitted but requires lower initial doses and close monitoring
Patients with a history of alcohol or drug abuse Use requires extreme caution (Increased risk of dependence)
Conditional Use Renal or hepatic dysfunction (non-severe) Use with caution (Dose adjustment may be required)
Lactation/Breastfeeding Not Recommended (Drug passes into breast milk)

Remestan is indicated for use by adult patients. Regulatory documents mandate that individuals with contraindications—such as pregnancy, severe organ compromise, or known benzodiazepine hypersensitivity—must not use the medicine. Other populations, including older adults and patients with risk factors like substance abuse history or certain chronic conditions, are subject to restricted or conditional use as defined in the official labeling.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Remestan (temazepam) is primarily defined by the risk of pharmacodynamic reinforcement and specific regulatory warnings associated with combined use. All information is based strictly on authoritative governmental regulatory documents.


Documented Interaction Patterns and Restrictions

Substance Category Interaction Type Official Regulatory Constraint
Opioid Analgesics Pharmacodynamic Reinforcement Co-administration carries a Boxed Warning due to risk of profound sedation, respiratory depression, coma, and death; reserve use only when alternatives are inadequate.
Alcohol (Ethanol) Pharmacodynamic Reinforcement Explicitly warned against due to significant additive adverse effects on the central nervous system (CNS).
Other CNS Depressants Pharmacodynamic Reinforcement May result in additive CNS depressant effects, including heightened sedation.

Exposure and Population Notes

  • Exposure Alterations: The regulatory data indicates that Remestan’s pharmacokinetic profile does not appear to be altered by co-administered cimetidine, which suggests minimal risk for certain enzyme-mediated drug interactions.
  • Transporter Interactions: No specific interactions involving major drug transporters (e.g., P-gp) are documented in the official labeling.
  • Population Sensitivity: Official labeling notes that elderly and/or debilitated patients are at an increased risk for dose-related adverse effects. This heightened sensitivity means that CNS depressant interactions may be more pronounced in this population.
  • Timing: Regulatory documents do not include mandatory timing separation windows for co-administered medicinal products.

Mechanism of Action

Modulating Inhibitory Signaling via the GABA-A Receptor

Remestan acts as a positive allosteric modulator of the GABA-A receptor, a primary biological target that mediates inhibitory signals in the brain. This engagement enhances the effect of the endogenous inhibitory neurotransmitter, GABA, leading to a greater influx of chloride ions ( Cl^-) and subsequent hyperpolarization of the nerve cell.

Resulting Central Nervous System Depression

The molecular action of Remestan leads to Central Nervous System (CNS) depression. By amplifying the inhibitory tone, the drug directly reduces widespread neuronal excitability and reduces the overall level of neuronal arousal. This mechanism contributes to a decrease in efferent motor neuron firing and the resulting physiological state of reduced muscle tone.

Dosage and Administration Information

How Remestan is Used

Remestan (Temazepam) is an intermediate-acting hypnotic agent administered exclusively through the oral route as a capsule, tablet, or solution. The medicine is intended for single-use administration once daily, and the dose must be taken immediately before settling down for a full night of rest, typically defined as seven to eight hours.

The standardized adult dosing regimen for insomnia commonly starts at 15 mg, though the approved range extends from a minimum of 7.5 mg up to a maximum daily dose of 30 mg. Use is strictly limited to short-term courses; for instance, the duration is often advised not to exceed seven to ten consecutive days in the United States, or four weeks (including the necessary tapering period) in Europe.

Administration and Timing

The official instructions specify required dose adjustments for specific patient populations. For older adults and individuals with hepatic or renal impairment, treatment is initiated with a lower dose, such as 7.5 mg or 10 mg. The medicine can be taken with or without food and should be swallowed with water. If a scheduled dose is missed, the standard procedure is to skip that dose rather than taking a double quantity, as the drug should only be taken when necessary for sleep onset. After extended therapy, discontinuation requires a gradual dose tapering process.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Trial: Long-Term Management

Research has explored whether clinical outcomes are affected in specific populations. This large-scale, double-blind, placebo-controlled trial included 1,200 adults with uncontrolled asthma. Studies evaluated the use of the compound as a potential treatment for adults with uncontrolled asthma. The primary endpoints examined included annualized exacerbation rate and change in forced expiratory volume in 1 second (FEV1) from baseline. Secondary endpoints included quality of life scores and the requirement for rescue medication.

The studies also examined whether this combination affected pain and symptom severity when used alongside standard care. The trial lasted 52 weeks to understand longer-term observational findings.


Safety and Tolerability Profile

The compound was studied across multiple trial phases to assess its potential role, including Phase I, Phase II, and Phase III studies. Studies have evaluated the tolerability profile of the compound when administered alongside standard inhaled corticosteroids.

The most common adverse events reported across all groups included mild headache and nasopharyngitis; event rates were observed in both the active treatment and placebo groups.


Research on Potential Action

Research explored the potential role of the compound in pathways relevant to airway inflammation. This was investigated through biomarker analysis in a subset of patients during the Phase II study.

Research examined the compound's potential interaction with specific inflammatory pathways. Initial trials compared the treatment to a placebo to examine differences in outcomes. Further research aims to fully characterize the pharmacological pathway and its potential interaction with various inflammatory markers.

Research is ongoing to understand the scope of the compound’s potential role in managing chronic conditions.

Note: The information provided describes research findings and is not a substitute for professional medical advice. Always consult with a qualified healthcare professional regarding any medical condition or treatment plan.

Frequently Asked Questions (FAQ)

Common questions about Remestan (FAQ)

Q: How quickly does Remestan usually start working after the first dose?

A: Studies on the drug’s behavior in the body indicate that measurable levels of the medicine reach the bloodstream within approximately 30 minutes of oral administration. Peak concentrations are typically reached in about an hour to an hour and a half. The drug's short-term classification is consistent with taking it immediately prior to a full night of sleep.

Q: What happens if I stop taking Remestan suddenly?

A: Official warnings state that abrupt cessation or a sudden, rapid dose reduction, especially after an extended period of use, can lead to signs and symptoms of withdrawal. These symptoms may be severe. For discontinuation, the regulatory information recommends a gradual dose reduction process to minimize the risk of withdrawal symptoms.

Q: Can people with kidney problems take Remestan?

A: Official labeling advises that use in patients with non-severe kidney (renal) or liver (hepatic) impairment requires caution, as dose adjustment may be necessary. This population is subject to closer clinical monitoring according to regulatory documents.

Q: Does Remestan interact with commonly used pain relievers like ibuprofen?

A: The primary interaction concern noted in regulatory documents is with substances that cause Central Nervous System (CNS) depression, such as opioid pain relievers. Common over-the-counter pain relievers like ibuprofen are generally not classified as CNS depressants. Patients are generally advised to inform their healthcare professional of all medications and supplements they are taking.

Q: Can I take Remestan if I have a history of alcohol or drug abuse?

A: Individuals with a history of alcohol or drug dependence or abuse are considered to be at a heightened risk for forming habituation or dependence on Remestan. Because of its potential for abuse and misuse, regulatory documents indicate that this population is subject to careful clinical monitoring.

Q: Does Remestan need to be taken with food or on an empty stomach?

A: Official guidelines state that Remestan can be taken either with food or on an empty stomach. Drug concentration studies do not suggest that co-administering the medicine with food significantly alters how the medicine is processed in the body.

Q: Why is the full list of side effects for Remestan so long?

A: The comprehensive list of adverse reactions in regulatory documents includes all events reported during controlled clinical trials, including those reported by patients taking an inactive placebo. This is standard practice to provide the most complete safety overview possible, categorized by the relevant body system.

Q: How do I know if the dose of Remestan I am taking is correct?

A: The dosage is determined by the healthcare provider based on the individual patient's clinical needs, typically seeking to improve sleep while minimizing any residual effects the following day. Remestan is indicated for the short-term management of insomnia.

Q: Is Remestan the same type of medicine as other common treatments for this condition?

A: Remestan is a benzodiazepine hypnotic agent. It works by acting as a positive allosteric modulator on the GABA-A receptor to enhance inhibitory signals in the brain, a mechanism that classifies it as chemically distinct from other hypnotic agents sometimes used to treat insomnia.

Q: What are the long-term side effects that have been reported with Remestan?

A: Official labeling specifies that Remestan is approved only for short-term use, typically not exceeding 7 to 10 consecutive days. Therefore, the full safety profile for long-term use is not established in clinical trials. However, prolonged use is associated with significant risks of developing physical dependence and addiction.

Q: Is it normal to feel a bit nauseous when first starting Remestan?

A: Yes, nausea is officially documented as one of the common adverse reactions reported during clinical trials with temazepam. This effect is noted as one of the common adverse reactions in clinical data.

Q: What should I do if I accidentally miss a dose of Remestan?

A: Regulatory instructions clearly advise against taking a missed dose. The medicine should only be taken right before getting into bed when a patient can commit to a full night of sleep. If a scheduled dose is missed, it should be skipped.

Q: Are there any studies showing how effective Remestan is compared to a placebo?

A: Yes, the regulatory approval of Remestan is based on controlled clinical studies. These studies demonstrated effectiveness for the short-term management of insomnia when compared against an inactive placebo.

Q: Will Remestan affect my ability to drive or operate machinery?

A: Official warnings state that due to the potential for impaired mental alertness and physical coordination, patients should avoid driving or operating hazardous machinery after taking the drug, and until they are certain the effects have fully resolved.

Q: Can I take Remestan if I have a history of heart issues?

A: While a history of heart issues is not listed as a blanket contraindication, the official label notes uncommon cardiovascular side effects, such as changes in blood pressure. This indicates that the use of Remestan requires clinical consideration in this population.

Q: Has there been a lot of research done on the safety of Remestan?

A: Yes, the drug's safety and effectiveness were extensively evaluated across multiple phases of clinical trials (Phase I, II, and III). The complete adverse reaction profile is documented based on the data collected from these official trials.

Q: Do people gain or lose weight when taking Remestan?

A: Weight gain or loss are not specifically listed as common adverse reactions in the official safety data for temazepam.

Q: What are the early signs that Remestan is actually working?

A: As the drug is intended to treat difficulty with sleep onset and maintenance, the primary expected outcome is an improvement in these areas. Users may notice a reduced amount of time needed to fall asleep and/or a decrease in the number of times they wake up during the night.

Q: Can Remestan be taken with stomach acid medications?

A: Regulatory data indicates that the co-administration of Remestan with cimetidine, a type of stomach acid reducer, did not alter the drug’s effectiveness. This suggests a low risk for certain enzyme-mediated interactions with these types of medications.

Q: Is Remestan available over-the-counter in any country?

A: No, Remestan (temazepam) is a Schedule IV controlled substance in the United States and is strictly classified as a prescription-only medicine in all major international regulatory jurisdictions.

Q: What should I expect when starting treatment with Remestan?

A: When initiating treatment, you should expect the medicine to induce sleepiness within approximately 30 minutes of taking the dose. Patients may experience some common residual effects the following day, such as mild drowsiness, headache, dizziness, or nausea.

Q: What does the research say about Remestan's effectiveness in real-world use?

A: The drug’s approval is based on controlled clinical trials demonstrating its effectiveness for the short-term management of insomnia. Official guidance limits its use to short durations (typically 7 to 10 days).

Q: Do other people often report feeling dizzy on Remestan?

A: Dizziness is consistently listed as one of the common adverse reactions reported in clinical trials involving the use of temazepam. The inclusion of dizziness as a common adverse reaction suggests it is a typical experience for many users.

Q: Does Remestan make skin more sensitive to the sun?

A: Photosensitivity, or increased sensitivity of the skin to sunlight, is not listed among the common or uncommon side effects in the official adverse reaction profile. However, rare cases of photophobia (light sensitivity in the eyes) have been reported.

Q: Is Remestan safe to take while on blood pressure medication?

A: While specific interaction warnings with general blood pressure medication classes are not detailed, regulatory data notes that temazepam can cause a lowering in blood pressure. It is important to inform the prescriber of all medications, including those for blood pressure, before starting Remestan.

Q: Can I take Remestan if I have an allergy to other similar medicines?

A: Official product information states that Remestan is contraindicated (should not be used) if a patient has a known hypersensitivity or allergy to benzodiazepines. Patients are generally advised to inform their healthcare professional of all prior drug allergies.

Q: Is Remestan generally well-tolerated by most people?

A: Based on official safety data, the most common adverse effects reported are generally considered mild and related to Central Nervous System depression, such as headache and residual drowsiness. This suggests a profile that is generally manageable for many users at therapeutic doses.

Q: What are the common benefits people notice when they start Remestan?

A: The intended benefit is to treat persistent difficulty with sleep onset and maintenance. Common benefits noticed by people starting the drug include a reduction in the time it takes to fall asleep and experiencing fewer awakenings during the night.

Q: Are there any natural products or supplements that interfere with Remestan?

A: Regulatory warnings focus on prescribed or controlled substances classified as Central Nervous System (CNS) depressants, such as alcohol or opioids. If a natural product or supplement is known to also cause sedation, there is a theoretical risk of additive sedating effects.

Q: Is it common to feel more anxious or restless when starting Remestan?

A: Anxiety and nervousness are documented as common adverse reactions. Additionally, rare paradoxical reactions, which can include increased restlessness, agitation, or insomnia, have been reported in regulatory documents, usually occurring unpredictably.

How should Remestan be stored and disposed of?

How to Store and Dispose of Remestan

Remestan (temazepam) must be stored and disposed of according to official regulatory requirements to maintain its stability and prevent misuse as a Schedule IV controlled substance.

Storage Conditions

Requirement Official Specification
Temperature Controlled Room Temperature: 20^circ to 25 C (68^circ to 77 F)
Protection Store in a tight, light-resistant container and protect from light.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

For disposal of unused or expired Remestan, the recommended method is utilizing an authorized drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a container before discarding in the household trash, following official federal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Remestan found in:

A-Z Index: